ML20217Q292

From kanterella
Revision as of 00:48, 1 March 2021 by StriderTol (talk | contribs) (StriderTol Bot insert)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Discusses 881209 Petition Submitted by Theragenics Corp Requesting Amend to 10CFR35.400 to Add Pd-103 as Sealed Source in Seeds for Interstitial Treatment of Cancer.Final Amend Published on 891012 in Fr
ML20217Q292
Person / Time
Issue date: 11/03/1989
From: Bahadur S
NRC OFFICE OF NUCLEAR REGULATORY RESEARCH (RES)
To: Cooper H
AFFILIATION NOT ASSIGNED
Shared Package
ML20217P754 List:
References
FOIA-98-86 NUDOCS 9804100377
Download: ML20217Q292 (2)


Text

p-

~) .

ga ato vy'o

! MN g UNITED STATES 8' n NUCLEAR REGULATORY COMMISSION

$ , 'y WASHINGTON, D. C. 20555 .

e, e ,

'49 ,O', (

i Nov o s 1989 /

) bl Mr/HowardT. Cooper Ibigulatory and Medical Affairs Director ,

i

%eragenics Corporation I

440TenthStreet,N.W.,SuiteN?10 Atlanta, Georgia' 30318 j

Dear Mr. Cooper:

On Mr 9,1988, % era'genics Cupuratica suhaitted a petition for rulemaking to the NRC. Se petition requested that the NRC amend 10 CFR 35.400 to add palladium-103 as a sealed source in seeds for j interstitial treatment of cancer. l 1

%e NRC considered the petition and dete mined that there will be minimal risk j if palladium-103 as a sealed sourm in seeds is used in aamrdanm with the

! manufacturer's radiation safety and handlity instructions. % erefore, the NRC published a final amcndment on Ct+% 12, 1989 in the Me.nl Reaister (54 FR 41819) . A copy of the Federal Register notice is enclosed for your information.

Sincerely,

Sher Bahadur, Chief Regulation Development Branch Division of Regulatory Applications Office of Nuclear Regulatory Researth

Enclosure:

FR notice i

l 9804100377 980407 l l~ PDR FOIA THOMPSON 98-86 PDR $

W-

)

Nov 0 3 Iggg Mr. Howard T. Cooper 7

Regulatory and Medical Affairs Director

'Iberagenics Corporation 430 'Ibnth Street, N.W., Suite N 210 Atlanta, Georgia 30318

Dear Mr. Cooper:

On C+wier 9,1988, 'Iheragenics Corporation subnitted a petition for rulemaking to the NRC. 'Ihe petition requested that the NRC amend 10 CFR 35.400 to add nalladium-103 as a sealed source in ==k for interstitial treatment of cancer. .

'Ihe NRC considered the petition and determined that there will be minimal risk if palladium-103 as a sealed source in seeds is used in accordance with the manufacturer's radiation safety and handling instructions. . 'Iherefore, the NRC published _a f%1 amendment on October 12, 189 in the Feder_al Recister (54 FR 41819). A copy of the Federal Register notice is enclosed for your information.

Sincerely, S

Sher Bahadur, 011ef Regulation Development Branch Division of Regulatory Applications Office of Nuclear Regulatory Research

Enclosure:

FR notice DISTRIRTI' ION: (w/o encl.)

Subj h n-circ RDB reading SBahadur JIblford l M.y ~ t Dalowe, NMSS l BGolden, AIN l LBo11ing, GPA l

OFF:- RDB/ RDB &

NAME: A'nq I Jfe ord SBahadur DATE: 10/:0/89, 10g/89 ,.20/02/89 18 L